Loading stock data…
BLLN
$72.12-5.37 (-6.93%)
After Hours$75.00+2.88 (+3.99%)· Last close May 4
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$72.12
Potential Downside
97%
Whystock Fair Value$2.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$116.71+61.8%
Range$90.00 – $145.00
Fundamentals
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.99B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
620.29
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.55%
Volume
Today's trading volume
697,366
Recent News
What Makes BillionToOne (BLLN) a Revolutionizer in Genetic Testing?
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value
In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.
Discover 3 Stocks That Might Be Trading Below Estimated Value
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
3 Companies That May Be Priced Below Their Estimated Value
Over the last 7 days, the United States market has remained flat, yet it is up 28% over the past year, with earnings forecast to grow by 16% annually. In such a climate, identifying stocks that may be priced below their estimated value can offer investors opportunities for potential growth as they seek companies with strong fundamentals and promising prospects.
Jim Cramer Believes “BillionToOne’s a Winner”
BillionToOne, Inc. (NASDAQ:BLLN) was among the stocks Jim Cramer covered on Mad Money as he discussed the wave of IPOs being the market’s possible biggest threat. When a caller inquired about the stock, Cramer said: We looked into BillionToOne. We think it’s a really good diagnostic company. Now, the diagnostic companies themselves have been going […]